Endoglin (ENG) is a TGF-β coreceptor and essential for vascular development and angiogenesis. A chimeric antihuman ENG (hENG) monoclonal antibody (mAb) c-SN6j (also known as TRC105) shows promising safety and clinical efficacy features in multiple clinical trials of patients with various advanced solid tumors. Here we developed a novel genetically engineered mouse model to optimize the ENG-targeting clinical trials. We designed a new targeting vector that contains exons 4-8 of hENG gene to generate novel genetically engineered mice (GEMs) expressing functional human/mouse chimeric (humanized) ENG with desired epitopes. Genotyping of the generated mice confirmed that we generated the desired GEMs. Immunohistochemical analysis demonstrated that humanized ENG protein of the GEMs expresses epitopes defined by 7 of our 8 anti-hENG mAbs tested. Surprisingly the homozygous GEMs develop normally and are healthy. Established breast and colon tumors as well as metastasis and tumor microvessels in the GEMs were effectively suppressed by systemic administration of anti-hENG mAbs. Additionally, test result indicates that synergistic potentiation of antitumor efficacy can be induced by simultaneous targeting of two distinct epitopes by anti-hENG mAbs. Sorafenib and capecitabine also showed antitumor efficacy in the GEMs. The presented novel GEMs are the first GEMs that express the targetable humanized ENG. Test results indicate utility of the GEMs for the clinically relevant studies. Additionally, we generated GEMs expressing a different humanized ENG containing exons 5-6 of hENG gene, and the homozygous GEMs develop normally and are healthy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353567 | PMC |
| http://dx.doi.org/10.1002/ijc.28994 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Downregulating human leucocyte antigens on mesenchymal stromal cells by epigenetically repressing a β-microglobulin super-enhancer.
Nat Biomed Eng
December 2024
Department of Sports Medicine of the Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.
Article Synopsis
- Immune rejection due to mismatched human leucocyte antigens (HLAs) poses a significant challenge for allogeneic cell therapies.
- Current methods to create 'universal' immune-compatible cells can lead to problems like genomic instability or cell damage.
- By targeting a specific super-enhancer linked to HLA-I expression in mesenchymal stromal cells, researchers were able to reduce HLA-I on the cell surface, enhancing their survival in a humanized mouse model and improving therapeutic outcomes in acute lung injury.
Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies.
Nat Biomed Eng
December 2024
Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Bispecific antibodies (biAbs) used in cancer immunotherapies rely on functional autologous T cells, which are often damaged and depleted in patients with haematological malignancies and in other immunocompromised patients. The adoptive transfer of allogeneic T cells from healthy donors can enhance the efficacy of biAbs, but donor T cells binding to host-cell antigens cause an unwanted alloreactive response. Here we show that allogeneic T cells engineered with a T-cell receptor that does not convert antigen binding into cluster of differentiation 3 (CD3) signalling decouples antigen-mediated T-cell activation from T-cell cytotoxicity while preserving the surface expression of the T-cell-receptor-CD3 signalling complex as well as biAb-mediated CD3 signalling and T-cell activation.
View Article and Find Full Text PDFA base editor for the long-term restoration of auditory function in mice with recessive profound deafness.
Nat Biomed Eng
August 2024
ENT Institute and Department of Otorhinolaryngology, Eye and ENT Hospital, Fudan University, Shanghai, China.
Article Synopsis
- A specific mutation in the OTOF gene is linked to severe hearing loss, which is studied using mutant mice that mimic this condition.
- Researchers used a base editor technique to correct the mutation in the inner ear of these mice, leading to significant restoration of hearing and otoferlin protein levels.
- The findings suggest that base editing could be a promising approach for treating hereditary deafness in humans.
Prevalence of preexisting articular bone pathology in patients with osteoarthritis screened for fasinumab clinical trials identified by X-ray or magnetic resonance imaging.
Osteoarthritis Cartilage
December 2024
Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Article Synopsis
- This study aimed to analyze how common existing joint bone issues are in patients with hip or knee pain from osteoarthritis (OA) who were screened for fasinumab clinical trials.
- Out of 27,633 screened participants, 21,997 underwent imaging, and 5.5% were excluded due to severe articular bone problems noted in X-rays or MRIs, such as bone fragmentation and osteonecrosis.
- The results suggest that around 5% of OA patients who qualified for the clinical trials ended up being excluded because of serious preexisting joint conditions detected during imaging tests.
Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium.
Cancer Res Commun
July 2024
Department of Physiology and Biophysics, College of Medicine, University of Illinois Chicago, Chicago, Illinois.
Unlabelled: Endothelial Notch signaling is critical for tumor angiogenesis. Notch1 blockade can interfere with tumor vessel function but causes tissue hypoxia and gastrointestinal toxicity. Notch4 is primarily expressed in endothelial cells, where it may promote angiogenesis; however, effective therapeutic targeting of Notch4 has not been successful.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!